• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.

作者信息

Mattsson C, Nyberg-Arrhenius V, Wallén P

出版信息

Thromb Res. 1981 Mar 15;21(6):535-45. doi: 10.1016/0049-3848(81)90254-1.

DOI:10.1016/0049-3848(81)90254-1
PMID:7022741
Abstract
摘要

相似文献

1
Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.在人工循环系统中组织型纤溶酶原激活剂、尿激酶和链激酶对血栓的溶解作用
Thromb Res. 1981 Mar 15;21(6):535-45. doi: 10.1016/0049-3848(81)90254-1.
2
Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
Thromb Diath Haemorrh. 1975 Sep 30;34(1):351.
3
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
4
Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
Haemostasis. 1987;17(4):238-44. doi: 10.1159/000215750.
5
Factor XIII cross-linking and the rate of fibrinolysis induced by streptokinase and urokinase.
Thromb Res. 1978 Feb;12(2):287-95. doi: 10.1016/0049-3848(78)90299-2.
6
Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
Thromb Res. 1979;15(3-4):497-504. doi: 10.1016/0049-3848(79)90155-5.
7
The acyl-enzymes and pro-urokinase: promising new thrombolytic agents.
Haemostasis. 1986;16 Suppl 3:33-7. doi: 10.1159/000215364.
8
[Molecular mechanisms of thrombolytic therapy].[溶栓治疗的分子机制]
Haemostasis. 1986;16 Suppl 4:3-15. doi: 10.1159/000215525.
9
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.组织型纤溶酶原激活剂用于进展性心肌梗死患者的冠状动脉溶栓治疗。
N Engl J Med. 1984 Mar 8;310(10):609-13. doi: 10.1056/NEJM198403083101001.
10
Influence of coagulation on the activation of plasminogen by streptokinase and urokinase.凝血对链激酶和尿激酶激活纤溶酶原的影响。
Thromb Haemost. 1979 Oct 31;42(3):901-8.

引用本文的文献

1
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.针对黑色素瘤细胞来源的66,000分子量人纤溶酶原激活物的单克隆抗体。特异性酶抑制及一步亲和纯化。
EMBO J. 1983;2(1):115-9. doi: 10.1002/j.1460-2075.1983.tb01391.x.
2
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.阿替普酶。对其在急性心肌梗死以外血管疾病中的药理学及治疗应用的重新评估。
Drugs. 1995 Aug;50(2):289-316. doi: 10.2165/00003495-199550020-00007.
3
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
阿替普酶。对其在急性心肌梗死中的药理特性及治疗用途的重新评估。
Drugs. 1995 Jul;50(1):102-36. doi: 10.2165/00003495-199550010-00008.
4
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.特异性抑制一种人类52,000道尔顿纤溶酶原激活酶的单克隆抗体。
Proc Natl Acad Sci U S A. 1982 Jun;79(12):3720-3. doi: 10.1073/pnas.79.12.3720.
5
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.通过单克隆抗体亲和纯化后鉴定出的来自人黑色素瘤细胞的组织型纤溶酶原激活物的无活性前体酶。
EMBO J. 1984 Jan;3(1):51-6. doi: 10.1002/j.1460-2075.1984.tb01760.x.
6
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.尿激酶型纤溶酶原激活物在Lewis肺癌中的免疫细胞化学定位
J Cell Biol. 1984 Aug;99(2):753-7. doi: 10.1083/jcb.99.2.753.
7
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.尿激酶型纤溶酶原激活物免疫反应性在小鼠体内的分布
J Cell Biol. 1984 Mar;98(3):894-903. doi: 10.1083/jcb.98.3.894.
8
Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.组织型纤溶酶原激活剂可增加谷氨酸纤溶酶原与血栓的结合。
J Clin Invest. 1984 Dec;74(6):2009-16. doi: 10.1172/JCI111623.
9
Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.由尿激酶或组织型纤溶酶原激活剂激活的血浆中纤溶酶原和纤溶酶抑制剂复合物分子形式的形成顺序。
Biochem J. 1984 Oct 1;223(1):179-87. doi: 10.1042/bj2230179.
10
Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis.链激酶、尿激酶和组织型纤溶酶原激活剂：药代动力学、相对优势以及使溶解速率和一致性最大化的方法。
Cardiovasc Intervent Radiol. 1986;9(5-6):236-44. doi: 10.1007/BF02577952.